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Objectives" To define current practice regarding the use of pharmacological prophylaxis to prevent postoperative graft 
occlusion. 
Design: Prospective open questionnaire. 
Materials and Methods: Questionnaires regarding this subject were sent to vascular surgeons throughout the world to 
analyse current practice. 
Results: 651 questionnaires were returned with a response rate of 62% and form the basis for this report. Data from 
100 334 vascular econstructions were reported in this survey. Prophylaxis against postoperative graft occlusions was 
common. Treatment periods were usually greater than 1 year. Among carotid surgery patients, 82% received prophylaxis, 
consisting mainly of low-dose acetysalieylic a id (ASA). In Mid-Europe the use of oral anticoagulation was more common 
than in other egions (p < 0.001). Among aneurysm surgery patients, 38% received prophylaxis. For infrainguinal bypass, 
ASA in low dose was the most commonly used agent worldwide. However, oral anticoagulation was more frequent in Mid- 
Europe, in contrast o South America where the combination of ASA and dipyridamole was most common. Considerable 
geographical differences regarding patient selection, the frequency of specific procedures and operative techniques 
existed. 
Conclusions" Important world-wide differences xist regarding prophylaxis for postoperative graft occlusion. 
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Introduction 
Adjuvant pharmacologic prophylaxis against graft 
occlusion following peripheral vascular surgery is 
common practice. However, well-conducted studies 
on this subject are few in number with the exception of 
antiplatelet prophylaxis following coronary artery 
1 bypass. The efficacy of such interventions for increas- 
ing graft patency has not been convincingly proven. 2-4 
Nevertheless, there is support for prophylaxis, uch as 
the cardioprotective effect 2'3 and data provided by 
metaanalysis by the Antiplatelet Trialist Collaboration 
which documented reduced cerebrovascular events 
mortality by use of antiplatelet agents 5 and anticoagu- 
lants. 3"6 In an attempt to define current practice 
patterns regarding this subject, a questionnaire was 
Please address all correspondence to: Bengt Lindblad, Department 
of Surger~ Lund University, Malm6 General Hospital, S-214 01 
Malta6, Sweden. 
used to survey the postoperative use of pharmaco- 
logical prophylaxis against graft occlusions in vas- 
cular surgery patients. 
Material and Methods 
All members of the Society for Vascular Surgery (SVS) 
and the European Society for Vascular Surgery (ESVS) 
were provided with questionnaires regarding pharma- 
cological prophylaxis in patients undergoing periph- 
eral vascular surgery. A total of 651 of the 1 045 
questionnaires were returned with a response rate of 
62% (Table 1). Responses were geographically divided 
between: North America, South America, Northern 
Europe (the Scandinavian countries), Mid-Europe, 
Southern Europe (the countries adjacent to the Medi- 
terranean Sea), Africa and Arabia, as well as Aus- 
tralasia. The survey also addressed intraoperativ e 
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Table 1. Number of respondents, response rate, and reported 
operations 
Number of Response Number of 
Region respondents rate (%) operations 
North America 284 73 40 395 
Northern Europe 74 80 8 146 
Mid-Europe 165 59 30 895 
Southern Europe 45 46 8 990 
Australasia 42 62 6 232 
South America 27 32 2 995 
Africa and Arabia 14 41 2 681 
Total 651 62 100 334 
anticoagulation, a subject presented elsewhere. 7 In the 
current report, the type and duration of postoperative 
pharmacologic prophylaxis was assessed for carotid 
endarterectomy, suprainguinal reconstruction for 
occlusive disease, elective and emergency abdominal 
aortic repair, infrainguinal reconstruction, throm- 
boembolectomy, and dialysis access. All questionnaire 
responses were entered into a computerised data-base 
(4th Dimension, ACIUS Inc., Cupertino, CA, US), and 
subjected to statistical evaluation using the 9~2 test. A 
confidence level of less than 5% was considered 
significant. 
Results 
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Fig. 1. Variation in carotid surgery for different geographical 
regions. 
occlusive disease was 1.6, with differences also noted 
geographically, asevident from the Mid-Europe ratio 
of 2.2 (p < 0.001), the Southern Europe ratio of 0.9, and 
the Africa and Arabia ratio of 1.1 (p < 0.005)(Fig. 3). 
Prophylaxis according to geographical region 
The use of long-term pharmacologic prophylaxis to 
increase patency of peripheral vascular reconstruc- 
tions world-wide is shown in Table 2. In carotid 
The questionnaires itemised ata for 100334 periph- ~ 30 
eral vascular surgical procedures. The number and '~ 
types of operations differed among various geo- 
graphic area~ reporting (Figs 1-3). For example, 
carotid endarterectomy accounted for only 10% of the ~ 20 
operative caseload from Northern Europe but 24% of '~ 
the caseload from North America (p < 0.001). Carotid 
endarterectomies n North America were performed 
with shunts in 58% of cases, compared to Mid-Europe ~ 10 
where 38% (p < 0.01) employed shunts, and in Africa 
and Arabia where only 19% used shunts (p < 0.01)(Fig. 
1). Other relevant differences existed. For instance, the 
world-wide ratio of elective to emergency operations ~ 0 
for abdominal aortic aneurysms was 3.0 with corre- 
sponding ratios for North America of 5.0 (p < 0.001), 
Northern Europe of 1.3 (p < 0.001), Mid-Europe of 2.4 
(p < 0.001), and 3.8 for the remaining regions (Fig. 2). 
Similarly, the world-wide ratio of suprainguinal 
bypasses to aorto-iliac reconstructions performed for 
Fig. 2. Variation in aortic abdominal aneurysm surgery for different 
geographical regions. 
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surgery the mean frequency of prophylaxis was 82% 
and no regional differences were noted. In other types 
of vascular procedures geographical differences were 
noted. Following suprainguinal reconstruction for 
occlusive disease the mean frequency of pharmaco- 
prophylaxis world-wide was 60%. Regional differ- 
ences were found: North America 51% (p<0.02); 
Northern Europe 40% (p<0.01); Mid-Europe 78% 
(p < 0.001); Southern Europe 72% (NS); Australasia 60% 
(NS); South America 73% (NS); and Africa and Arabia 
73% (NS). With regard to aneurysm surgery, variations 
in prophylaxis from the world-wide mean of 38% 
were: North America 31% (p < 0.05); Northern Europe 
23% (p < 0.01); Mid-Europe 52% (p < 0.005); Southern 
Europe 57% (p<0.01); Australasia 30% (NS); South 
America 36% (NS); and Africa and Arabia 54% (NS). 
Prophylaxis rates for dialysis access also varied from a 
world-wide mean of 32%, being: North America 31% 
(NS); Northern Europe 22% (p < 0.05); Mid-Europe 38% 
(p < 0.02); Southern Europe 44% (p < 0.02); Australasia 
36% (NS); South America 21% (p < 0.05); and Africa and 
Arabia 46% (p < 0.05). 
Type of prophylaxis 
The type of pharmacologic agent used is shown in 
Table 3 and this also differed according to region. For 
instance, differences in use of low dose ASA from a 
world-wide mean use in 57% of cases occurred: 
Southern Europe (42%, p < 0.01, the lowest use), and in 
Northern Europe (78%, p < 0.005, the highest use). Oral 
anticoagulation following carotid surgery was used 
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Fig. 3. Variation in limb revascularisation f r different geographical 
regions. 
Table 2. World-wide longterm postoperative pharmacological 
prophylaxis according to the type of vascular procedure (%) 
Difficult 
Routine cases Rarely Never 
Carotid surgery 
with shunt 78 4 8 10 
Carotid surgery 
without shunt 77 4 7 11 
Elective aneurysm 
repair 32 6 25 37 
Emergency aneurysm 
repair 31 6 24 39 
Suprainguinal reconstruction 
for occlusive disease 
Infrainguinal 
reconstruction 
Thromboembolectomy 
A-V shunts 
50 10 22 18 
69 17 10 4 
75 11 9 5 
24 8 31 37 
world-wide in 5% of cases, compared to Mid-Europe 
use of 10%, p<0.01). In Southern Europe 17% of 
carotid surgery patients were given other antiplatelet 
agents, mainly ticlopidine. Among patients under- 
going suprainguinal reconstruction for occlusive dis- 
ease, variations occurred mainly in the use of oral 
anticoagulation. World-wide use of these agents was 
15% compared to: Africa and Arabia 0% (p < 0.05); 
South America 0% (p<0.05); Southern Europe 6% 
(p < 0.05); North America 6% (p < 0.01); Northern 
Europe 12% (NS); Australasia 26% (p < 0.01) and Mid- 
Europe 35% (p < 0.001). In Southern Europe 25% of the 
patients undergoing suprainguinal reconstruction 
were given other pharmacological prophylaxis. Sur- 
prisingly, 25% of patients undergoing aortic aneurysm 
surgery in Mid-Europe received oral anticoagulation 
(p<0.001). Pharmacologic prophylaxis after infra- 
inguinal reconstructions also varied geographically. 
The mean world-wide use of low dose ASA was 37% 
compared to: North America, 42%, (NS); Northern 
Europe 49%, (p < 0.05); and Australasia, 41% (NS). A 
combination of ASA and dipyridamole was used in 
16% of cases world-wide, compared to: South Amer- 
ica, 45%, (p < 0.005). Oral anticoagulation was used in 
34% of cases world-wide, compared to: Mid-Europe, 
53%, (p < 0.001) and North America, 24%, (p < 0.005). 
Duration of prophylaxis 
The world-wide duration of prophylaxis used is 
shown in Table 4. Geographic differences in the 
Eur J Vasc Endovasc Surg Vol 9, April 1995 
270 B. Lindblad et aL 
Table 3~ World-wide longterm postoperative pharmacological prophylaxis comparing the agent used according to the type of vascular 
procedure (%) 
ASA ASA ASA and Oral No 
< 325 mg > 325 mg Dipyridamole anticoagulants Other prophylaxis 
Carotid surgery 
with shunt 57 11 16 5 3 10 
Carotid surgery 
without shunt 56 10 16 5 3 10 
Elective aneurysm 
repair 31 8 10 9 2 39 
Emergency aneurysm 
repair 30 7 10 7 2 41 
Suprainguinal reconstruction 
for occlusive disease 
Infrainguinal 
reconstruction 
Thromboembolectomy 
A-V shunts 
42 8 13 15 3 18 
37 7 16 34 3 4 
23 6 9 55 3 5 
28 5 8 14 4 41 
Table 4. World-wide duration of postoperative pharmacological 
prophylaxis according to the type of vascular procedure (%) 
TIME (months) < 1 1-3 3-6 6-12 > 12 
Carotid surgery 
with shunt 2 6 9 8 75 
Carotid surgery 
without shunt 2 7 9 9 74 
Elective aneurysm 
repair 2 8 14 10 66 
Emergency aneurysm 
repair 2 8 12 10 68 
Suprainguinal reconstruction 
for occlusive disease 
Infrainguinal 
reconstruction 
A~V shunts 
1 6 10 10 73 
0.3 3 13 9 74 
9 11 7 8 66 
duration of pharmacologic prophylaxis also occurred. 
In the majority of cases prophylaxis continued for 
more than 1 year. Following carotid surgery, 50% of 
patients in Northern Europe, were treated for less than 
6 months compared to 11% in North America 
(p < 0.001) and 18% in Mid-Europe (p < 0.01). A shorter 
treatment period of < 6 months in Northern Europe 
also followed infrainguinal reconstructions (28%) and 
thrornboembolectomy (32%). Corresponding figures 
for North America were 9% and 13% (p < 0.05); and for 
Mid-Europe 8% and 16% (p < 0.05). All other regions 
used longer treatment periods. 
Discussion 
Pharmacologic prophylaxis aimed at improving 
patency after vascular econstructions is largely based 
upon studies suggesting benefits in the prevention of 
cerebral and cardiac morbidity and mortality. 2~3 The 
salutatory results attributed to antiplatelet or oral 
anticoagulation therapy in various arteriosclerotic risk 
groups have contributed to widespread use of these 
agents among vascular surgeons. However, prospec- 
tive randomised studies evaluating the effect of such 
interventions on patency in peripheral vascular sur- 
gery are few. 4 
The differing response rate in this survey must be 
considered when examining the data from a specific 
region. Similarly, the number of specific procedures 
varied widely between regions. Such differences limit 
the ability to make firm conclusions from the present 
data. For example in Northern Europe about 50% of 
vascular reconstructions were reported, 8 whilst in 
North America less than 10% were reported. 9 The 
statistical analysis used gives a risk of false-positive 
results but use of Bonfioni's correction for multiple 
analysis would have increased the risk of false- 
negative results. Nevertheless ome geographic differ- 
ences are noteworthy. The ratio of elective and 
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emergency aneurysm repair in different regions varied 
from 1.3 to 5.0. Similarly, the ratio between infra- 
inguinal to suprainguinal bypass for occlusive disease 
varied from 0.9 to 2.2. Whether this represents 
epidemiologic differences in the distribution of arteri- 
osclerosis or different attitudes among vascular sur- 
geons in selecting patients is unclear. 
The use of pharmacologic prophylaxis following 
carotid surgery was common. The evidence support- 
ing antiplatelet therapy after surgery in these circum- 
stances is scant, 1° but extrapolation from other clinical 
studies made the use of such prophylaxis common, 
and a recently published series from Malm6 revealed 
a beneficial effect of low-dose ASA (75rag) after 
carotid surgery. 11 In suprainguinal reconstructions the 
use of prophylaxis varied from 40 to 78%. In Mid- 
Europe oral anticoagulation was used in 35% of 
suprainguinal reconstructions. This appears to be 
based on studies showing decreased mortality from 
such treatment. 3 Larger, well-conducted studies on the 
use of oral anticoagulants after vascular surgery 
appear necessary. A problem in assessing the efficacy 
of such prophylaxis in suprainguinal reconstructions 
is the already high patency rates, making studies 
difficult because of the extraordinarily arge sample 
sizes needed to demonstrate significant differences. 
Furthermore, the bleeding risk of oral anticoagulation 
is substantial, especially in elderly patients, and the 
risk increases with the duration of the treatment 
period. 12 Thus oral anticoagulation is avoided by 
many surgeons. The majority of centres used low-dose 
ASA treatment which seems to give an equal cardio- 
protective effect as high-dose ASA but with less 
complications from the treatment. 
The frequent use of ASA in patients with clini- 
cally overt arteriosclerosis complicates placebo-con- 
trolled studies on grafts. In as much as restenosis and 
graft occlusion are likely to be multifactorial in their 
cause, the sample size needs to be large and laboratory 
markers for defining compliance to the treatment 
protocol seems necessary. 13 In Southern Europe new 
types of antiplatelet drugs such as ticlopidine have 
been liberally used while surgeons in North America 
and Northern Europe are more conservative. In some 
circumstances, differences depend on whether there is 
approval from the health authorities for clinical use of 
these substances. Another obvious regional difference 
was the 21 to 44% variation in pharmacologic prophy- 
laxis in uraemic patients undergoing dialysis access 
surgery. In these patients platelet function is already 
depressed, and prophylaxis seems less justified 
than in other patients undergoing vascular 
reconstructions. 
This study confirms that the majority of vascular 
surgeons recommend low-dose ASA following arterial 
reconstructive surgery. Among patients having infra- 
inguinal reconstruction and thromboembolectom~ 
oral anticoagulation is commonly used, especially in 
Mid-Europe. Geographical differences in the type of 
operations performed and the relevance of this to 
prophylaxis against postoperative graft occlusion 
deserves further study. 
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